Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

The Largest Pharmaceutical Lawsuits in History

Jan 24, 2025

Introduction to Pharmaceutical Lawsuits

The pharmaceutical industry is a complex and highly regulated sector. While it plays a vital role in advancing healthcare and improving patient outcomes, it has also faced significant legal challenges over the years. Some of the largest pharmaceutical lawsuits in history have resulted from issues such as misleading advertising, unsafe products, and unethical business practices. These cases highlight the critical importance of transparency and accountability in the industry.

pharmaceutical lawsuit

The Notorious Case of Purdue Pharma

One of the most well-known pharmaceutical lawsuits involved Purdue Pharma, the maker of OxyContin. The company faced numerous lawsuits alleging that it misled doctors and patients about the addictiveness of its opioid painkiller. In 2020, Purdue Pharma agreed to a settlement exceeding $8 billion in a federal case. Additionally, the company's owners, the Sackler family, agreed to pay $4.5 billion as part of a separate settlement with state attorneys general.

This case sheds light on the opioid crisis in the United States and the responsibility of pharmaceutical companies to market their products ethically. It also underscores the devastating impact that misleading information can have on public health.

GlaxoSmithKline's Record-Setting Settlement

Another major lawsuit involved GlaxoSmithKline (GSK), which in 2012 reached a $3 billion settlement with the U.S. government. This remains one of the largest healthcare fraud settlements in history. GSK was accused of promoting drugs for unapproved uses, failing to report safety data, and offering kickbacks to medical professionals.

pharmaceutical fraud

The settlement addressed allegations concerning several drugs, including Paxil and Avandia. This case highlighted the potential consequences of prioritizing profits over patient safety and the importance of adhering to regulatory guidelines.

Johnson & Johnson's Legal Battles

Johnson & Johnson has faced numerous lawsuits over its talcum powder products, with plaintiffs claiming they were linked to ovarian cancer. In 2020, the company was ordered to pay $2.1 billion in damages to women who developed cancer after using these products. This legal battle is part of a larger issue concerning product safety and corporate responsibility.

These lawsuits emphasize the necessity for companies to conduct thorough research and testing on their products before releasing them to the market. Ensuring consumer safety should always be a top priority for any business.

product safety

The Impact on the Pharmaceutical Industry

The repercussions of these legal battles extend beyond financial settlements. They have prompted companies to reevaluate their practices and implement stricter compliance measures to avoid future litigation. The increased scrutiny has led to more robust regulatory frameworks, ensuring greater transparency and ethical conduct within the industry.

The lessons learned from these cases serve as a reminder of the power of accountability and vigilance in safeguarding public health. As the industry continues to evolve, maintaining trust with consumers will remain a crucial aspect of pharmaceutical operations.

For up to date information, refer to the ViolationTracker : LINK